Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.
Cortellini A, Friedlaender A, Banna GL, Porzio G, Bersanelli M, Cappuzzo F, Aerts JGJV, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Berardi R, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Inno A, Di Marino P, Mansueto G, Zoratto F, Santoni M, Tudini M, Ghidini M, Filetti M, Catino A, Pizzutilo P, Sala L, Occhipinti MA, Citarella F, Russano M, Torniai M, Cantini L, Follador A, Sforza V, Nigro O, Ferrara MG, D'Argento E, Leonetti A, Pettoruti L, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Bertolini F, Della Gravara L, Dal Bello MG, Belderbos RA, De Filippis M, Cecchi C, Ricciardi S, Donisi C, De Toma A, Proto C, Addeo A, Cantale O, Ricciuti B, Genova C, Morabito A, Santini D, Ficorella C, Cannita K. Cortellini A, et al. Among authors: chiari r. Clin Lung Cancer. 2020 Nov;21(6):498-508.e2. doi: 10.1016/j.cllc.2020.06.010. Epub 2020 Jun 21. Clin Lung Cancer. 2020. PMID: 32680806
Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.
Metro G, Chiari R, Duranti S, Siggillino A, Fischer MJ, Giannarelli D, Ludovini V, Bennati C, Marcomigni L, Baldi A, Giansanti M, Minotti V, Crinò L. Metro G, et al. Among authors: chiari r. Lung Cancer. 2012 Oct;78(1):81-6. doi: 10.1016/j.lungcan.2012.06.005. Epub 2012 Jul 4. Lung Cancer. 2012. PMID: 22770374
Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Metro G, Chiari R, Bennati C, Cenci M, Ricciuti B, Puma F, Flacco A, Rebonato A, Giannarelli D, Ludovini V, Bellezza G, Ferolla P, Minotti V, Crinò L. Metro G, et al. Among authors: chiari r. Clin Lung Cancer. 2014 Jan;15(1):86-92. doi: 10.1016/j.cllc.2013.08.002. Epub 2013 Oct 17. Clin Lung Cancer. 2014. PMID: 24139827
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
Landi L, Tiseo M, Chiari R, Ricciardi S, Rossi E, Galetta D, Novello S, Milella M, D'Incecco A, Minuti G, Tibaldi C, Salvini J, Facchinetti F, Haspinger ER, Cortinovis D, Santo A, Banna G, Catino A, GiajLevra M, Crinò L, de Marinis F, Cappuzzo F. Landi L, et al. Among authors: chiari r. Clin Lung Cancer. 2014 Nov;15(6):411-417.e4. doi: 10.1016/j.cllc.2014.07.002. Epub 2014 Aug 16. Clin Lung Cancer. 2014. PMID: 25242668 Free article.
Future options for ALK-positive non-small cell lung cancer.
Iacono D, Chiari R, Metro G, Bennati C, Bellezza G, Cenci M, Ricciuti B, Sidoni A, Baglivo S, Minotti V, Crinò L. Iacono D, et al. Among authors: chiari r. Lung Cancer. 2015 Mar;87(3):211-9. doi: 10.1016/j.lungcan.2014.12.017. Epub 2015 Jan 3. Lung Cancer. 2015. PMID: 25601484 Review.
Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study.
Barni S, Maiello E, Di Maio M, Ardizzoni A, Cappuzzo F, Maranzano E, Novello S, Bennati C, Ori A, Rizzoli S, Crinò L; RIGHT-3 study group. Barni S, et al. Lung Cancer. 2015 Nov;90(2):234-42. doi: 10.1016/j.lungcan.2015.08.005. Epub 2015 Aug 19. Lung Cancer. 2015. PMID: 26314614 Free article.
Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis.
Chiari R, Metro G, Iacono D, Bellezza G, Rebonato A, Dubini A, Sperduti I, Bennati C, Paglialunga L, Burgio MA, Baglivo S, Giusti R, Minotti V, Delmonte A, Crinò L. Chiari R, et al. Lung Cancer. 2015 Nov;90(2):255-60. doi: 10.1016/j.lungcan.2015.09.009. Epub 2015 Sep 14. Lung Cancer. 2015. PMID: 26395848
Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer.
Metro G, Chiari R, Ricciuti B, Rebonato A, Lupattelli M, Gori S, Bennati C, Castrioto C, Floridi P, Minotti V, Chiarini P, Crinò L. Metro G, et al. Among authors: chiari r. Expert Opin Pharmacother. 2015;16(17):2601-13. doi: 10.1517/14656566.2015.1094056. Epub 2015 Oct 6. Expert Opin Pharmacother. 2015. PMID: 26439599
206 results